Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Dow
Medtronic
McKesson
Harvard Business School

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RADIUM RA-223 DICHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Radium Ra-223 Dichloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00699751 A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Completed Bayer Phase 3 2008-06-01 ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.
NCT01516762 Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases No longer available Bayer N/A 1969-12-31 This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.
NCT01618370 Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases Completed Bayer Phase 3 2012-07-01 This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.
NCT01810770 Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis Active, not recruiting Bayer Phase 3 2013-03-01 To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
NCT01833520 Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma Active, not recruiting Bayer Phase 1/Phase 2 2013-10-01 The goal of this clinical research study is to find the highest tolerable dose of radium-223 dichloride that can be given to patients with osteosarcoma. Radium-223 chloride is designed to work like radiation therapy in cells that are actively making bone. It is designed to target new bone growth in and around bone cancer and may kill cancer cells.
NCT01833520 Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma Active, not recruiting M.D. Anderson Cancer Center Phase 1/Phase 2 2013-10-01 The goal of this clinical research study is to find the highest tolerable dose of radium-223 dichloride that can be given to patients with osteosarcoma. Radium-223 chloride is designed to work like radiation therapy in cells that are actively making bone. It is designed to target new bone growth in and around bone cancer and may kill cancer cells.
NCT01934790 Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases Active, not recruiting Bayer Phase 1/Phase 2 2013-12-01 Eligible subjects must have completed 6 doses of treatment of radium-223 dichloride and experienced no radium-223 dichloride-related SAEs (serious adverse events) or CTCAE (Common Terminology Criteria for Adverse Events) Grade 3 or 4 adverse event during or after the initial course of radium-223 dichloride that led to the discontinuation of treatment. 40 Subjects will be enrolled and will receive up to 6 doses of radium-223 dichloride 50 kBq/kg IV every 4 weeks. The subject will be evaluated for AEs (adverse events) and laboratory tests at each visit every 4 weeks, prior to receiving radium-223 dichloride. After the end of treatment visit the subjects will enter the active follow up period. Related AEs and SAEs and Lab tests will be evaluated at each visit every 4 weeks for the first 12 weeks, then every 12 weeks for up to 2 years after the last dose of radium-223 dichloride. After the 2 years of active follow-up, subjects will enter the long-term follow-up period and will be followed via telephone follow-up at 6-month intervals for late toxicities and survival up to 7 years after the last dose of radium-223 dichloride or until death. Joint safety reviews will regularly take place to oversee safety of the subjects conducted at regular intervals. An interim analysis of the safety data will be conducted during the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Radium Ra-223 Dichloride

Condition Name

Condition Name for Radium Ra-223 Dichloride
Intervention Trials
Prostatic Neoplasms 7
Bone Metastases 4
Prostate Cancer 3
Breast Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Radium Ra-223 Dichloride
Intervention Trials
Prostatic Neoplasms 19
Neoplasm Metastasis 8
Bone Marrow Diseases 3
Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Radium Ra-223 Dichloride

Trials by Country

Trials by Country for Radium Ra-223 Dichloride
Location Trials
United States 186
United Kingdom 53
Italy 50
Germany 48
Spain 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Radium Ra-223 Dichloride
Location Trials
California 11
New York 11
Pennsylvania 9
Maryland 9
Louisiana 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Radium Ra-223 Dichloride

Clinical Trial Phase

Clinical Trial Phase for Radium Ra-223 Dichloride
Clinical Trial Phase Trials
Phase 3 4
Phase 2 12
Phase 1/Phase 2 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Radium Ra-223 Dichloride
Clinical Trial Phase Trials
Active, not recruiting 8
Not yet recruiting 7
Recruiting 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Radium Ra-223 Dichloride

Sponsor Name

Sponsor Name for Radium Ra-223 Dichloride
Sponsor Trials
Bayer 16
National Cancer Institute (NCI) 2
Carolina Research Professionals, LLC 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Radium Ra-223 Dichloride
Sponsor Trials
Industry 21
Other 13
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Colorcon
Boehringer Ingelheim
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.